Analyzing cannabis flowers according to the German Pharmacopeia - monograph 2018

Significance of the Topic

The legalization and strict regulation of medicinal cannabis in Germany since 2017 have created a growing demand for accurate, validated analytical methods to ensure product quality. High-performance liquid chromatography (HPLC) based assays compliant with the German Pharmacopeia monograph provide a robust framework for quantifying key cannabinoids in plant material. Reliable analysis supports safe dosing, regulatory compliance, and consistent therapeutic outcomes.

Objectives and Study Overview

This application note demonstrates the implementation and verification of the DAB 2018 monograph for analyzing six major cannabinoids (CBD, CBDA, CBN, Δ8-THC, Δ9-THC, Δ9-THCA) in medicinal cannabis flowers using the KNAUER AZURA HPLC plus system. The study aims to confirm method performance characteristics by analyzing a market-authorized cannabis flower sample (bediol) and comparing retention data against pharmacopeial specifications.

Methodology and Instrumentation

Cannabis flower samples were ground and extracted with ethanol according to the DAB protocol. The extracts were centrifuged, combined, diluted, and filtered prior to injection. Separation was achieved on an Eurospher II C18P column (150 x 3 mm, 3 µm) at 40°C with a gradient of water (phosphoric acid) and acetonitrile. Detection was performed at dual wavelengths (225 nm and 306 nm).

Used Instrumentation

• AZURA P 6.1 L pump
• AZURA MWD 2.1 L multi-wavelength detector
• AS 6.1 L autosampler
• CT 2.1 column thermostat
• Eurospher II C18P, 150 x 3 mm, 3 µm column

Main Results and Discussion

The method achieved clear separation of the six cannabinoids within 20 minutes, with critical resolution (Δ8-THC/Δ9-THC) of 1.3, exceeding the DAB requirement of R>1.2. Repeatability for five cannabinoids showed relative standard deviations below 1%. Retention factors for all analytes matched pharmacopeial values within acceptable limits. Additional peaks in the sample chromatogram likely correspond to minor cannabinoids or matrix components. Dual-wavelength detection effectively differentiated acidic and neutral cannabinoid forms.

Applications and Practical Benefits

• Ensures compliance with German regulatory standards for medicinal cannabis.
• Provides high throughput and reproducibility for quality control laboratories.
• Supports accurate labeling and dosage determination in pharmaceutical and nutraceutical products.

Future Trends and Opportunities

Analytical developments may include ultra-high performance liquid chromatography (UHPLC) for faster separations, mass spectrometry for enhanced specificity, and expanded cannabinoid profiling to include novel or minor compounds. Integration of automated sample preparation and data analysis with machine learning could further improve efficiency and traceability in cannabis quality control.

Conclusion

The KNAUER AZURA HPLC plus system effectively implements the DAB 2018 monograph for quantifying six principal cannabinoids in cannabis flowers. The method demonstrates robust separation, high precision, and compliance with pharmacopeial criteria, making it suitable for routine quality control of medicinal cannabis products.

References

• German Narcotics Law (BtMG), Federal Law Gazette, 2018 amendment.
• German Pharmacopeia (DAB), Cannabis flos monograph, 2018.
• Hoch et al., Cannabis: A Scientific Review, Springer, 2018.
• Grotenhermen, The Endocannabinoid System, in Handbook of Psychoactive Substances, Springer, 2018.
• Smith, Inter-lab Variation in the Cannabis Industry, Cannabis Science and Technology, 2019.
• Loxterkamp & Monks, Analyzing Cannabis Flowers According to DAB 2017, KNAUER, 2019.